Dr. Gibson is an interventional cardiologist, cardiovascular researcher, and educator who pioneered our understanding of the “open artery hypothesis” and the importance of restoring flow downstream in the capillary bed in the “open microvasculature hypothesis.” He has led trials that eventuated in the approval of drugs like prasugrel, rivaroxaban, and betrixaban. He is CEO of the combined entities of the Baim Institute and the PERFUSE Study Group, which together have conducted 1,030+ studies through their network of 7,000 sites worldwide, have participated in 100+ FDA submissions and have published their work in 3,000+ peer reviewed publications in major journals. He is the founder and Editor-in-Chief of wikidoc.org, the most widely viewed open source textbook of medicine, and the founder of clinicaltrialresults.org, where he has conducted over 2,000 video interviews. Dr. Gibson was named one of the world’s most widely published and cited scientists of past decade in 2014 by Thomson Reuters. He has held numerous leadership positions in medicine, including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology, and as a Vice Chairman of Medicine.